Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 5, Issue 1
  5. Article
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Chronic Lung Diseases (CLDs) constitute one of the most frequent causes of pulmonary hypertension (PH) and rank second after PH due to left heart disease. In PH-CLD, destruction of lung parenchyma is associated with decreased functional capacity, diminished quality of life, increased oxygen requirements, and a heightened risk of death.

As both pulmonary arterial hypertension (PAH) and PH due to lung disease are categorized as precapillary PH, it is essential to distinguish between the two conditions, particularly when the lung disease is present with the severe form of PH. If the diagnosis confirms a severe form of PH-CLD, then individualised care is essential in patients with severe lung disease and evidence of right-sided heart failure, particularly those with lower-limb oedema. Moreover, echocardiography (ECHO) and N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) evaluation are of high importance and must be ordered by the pulmonologist. Right Heart Catheterisation (RHC) is also essential for the determination of the extent and severity of pulmonary vascular involvement. The use of inhaled vasodilators, along with a referral for right heart catheterisation, should be considered at an earlier phase of interstitial lung disease. In addition to therapy, cardiopulmonary rehabilitation programmes have been found to improve six-minute walking tests (6MWT), oxygenation, and functional capacity.

This article discusses the screening of PH-CLD along with the treatment algorithm and suggests the promising role of vasodilators in PH-CLD.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882333573241119082734
2024-01-01
2025-07-10

  • From This Site

    /content/journals/nemj/10.2174/0102506882333573241119082734
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. NathanS.D. BarberaJ.A. GaineS.P. HarariS. MartinezF.J. OlschewskiH. OlssonK.M. PeacockA.J. Pepke-ZabaJ. ProvencherS. WeissmannN. SeegerW. Pulmonary hypertension in chronic lung disease and hypoxia.Eur. Respir. J.2019531180191410.1183/13993003.01914‑201830545980
     [Google Scholar]
  2. SakkijhaH. IdreesM. Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: Pulmonary hypertension due to lung diseases and/or hypoxia.Ann. Thorac. Med.201495Suppl. 15610.4103/1817‑1737.13403025076998
     [Google Scholar]
  3. HumbertM. KovacsG. HoeperM.M. BadagliaccaR. BergerR.M.F. BridaM. CarlsenJ. CoatsA.J.S. Escribano-SubiasP. FerrariP. FerreiraD.S. GhofraniH.A. GiannakoulasG. KielyD.G. MayerE. MeszarosG. NagavciB. OlssonK.M. Pepke-ZabaJ. QuintJ.K. RådegranG. SimonneauG. SitbonO. ToniaT. ToshnerM. VachieryJ.L. Vonk NoordegraafA. DelcroixM. RosenkranzS. SchwerzmannM. Dinh-XuanA.T. BushA. AbdelhamidM. AboyansV. ArbustiniE. AsteggianoR. BarberàJ.A. BeghettiM. ČelutkienėJ. CikesM. CondliffeR. de ManF. FalkV. FauchierL. GaineS. GaliéN. Gin-SingW. GrantonJ. GrünigE. HassounP.M. HellemonsM. JaarsmaT. KjellströmB. KlokF.A. KonradiA. KoskinasK.C. KotechaD. LangI. LewisB.S. LinhartA. LipG.Y.H. LøchenM.L. MathioudakisA.G. MindhamR. MoledinaS. NaeijeR. NielsenJ.C. OlschewskiH. OpitzI. PetersenS.E. PrescottE. RakishevaA. ReisA. RistićA.D. RocheN. RodriguesR. Selton-SutyC. SouzaR. SwiftA.J. TouyzR.M. UlrichS. WilkinsM.R. WortS.J. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.Eur. Heart J.202243383618373110.1093/eurheartj/ehac23736017548
     [Google Scholar]
  4. AndersenC. MellemkjærS. HilbergO. BendstrupE. NT-proBNP <95 ng/l can exclude pulmonary hypertension on echocardiography at diagnostic workup in patients with interstitial lung disease.Eur. Clin. Respir. J.2016313202710.3402/ecrj.v3.3202727478030
     [Google Scholar]
  5. NathanS.D. Progress in the treatment of pulmonary hypertension associated with interstitial lung disease.Am. J. Respir. Crit. Care Med.2023208323824610.1164/rccm.202212‑2342CI37159942
     [Google Scholar]
  6. LouvarisZ. VogiatzisI. Physiological basis of cardiopulmonary rehabilitation in patients with lung or heart disease.Breathe (Sheff.)201511212012710.1183/20734735.02111426306112
     [Google Scholar]
  7. GrünigE. EichstaedtC. BarberàJ.A. BenjaminN. BlancoI. BossoneE. CittadiniA. CoghlanG. CorrisP. D’AltoM. D’AndreaA. DelcroixM. de ManF. GaineS. GhioS. GibbsS. GumbieneL. HowardL.S. JohnsonM. JurevičienėE. KielyD.G. KovacsG. MacKenzieA. MarraA.M. McCaffreyN. McCaugheyP. NaeijeR. OlschewskiH. Pepke-ZabaJ. ReisA. SantosM. SaxerS. TullohR.M. UlrichS. Vonk NoordegraafA. PeacockA.J. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension.Eur. Respir. J.2019532180033210.1183/13993003.00332‑201830578391
     [Google Scholar]
  8. WalshS.L.F. DevarajA. EnghelmayerJ.I. KishiK. SilvaR.S. PatelN. RossmanM.D. ValenzuelaC. VancheriC. Role of imaging in progressive-fibrosing interstitial lung diseases.Eur. Respir. Rev.20182715018007310.1183/16000617.0073‑201830578332
     [Google Scholar]
  9. MerelesD. EhlkenN. KreuscherS. GhofraniS. HoeperM.M. HalankM. MeyerF.J. KargerG. BussJ. JuengerJ. HolzapfelN. OpitzC. WinklerJ. HerthF.F.J. WilkensH. KatusH.A. OlschewskiH. GrünigE. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension.Circulation2006114141482148910.1161/CIRCULATIONAHA.106.61839716982941
     [Google Scholar]
  10. FoxB.D. KassirerM. WeissI. RavivY. PeledN. ShitritD. KramerM.R. Ambulatory rehabilitation improves exercise capacity in patients with pulmonary hypertension.J. Card. Fail.201117319620010.1016/j.cardfail.2010.10.00421362526
     [Google Scholar]
  11. KabitzH.J. BremerH.C. SchwoererA. SonntagF. WalterspacherS. WalkerD.J. EhlkenN. StaehlerG. WindischW. GrünigE. The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension.Lung2014192232132810.1007/s00408‑013‑9542‑924338088
     [Google Scholar]
  12. ShoemakerM.J. WiltJ.L. DasguptaR. OudizR.J. Exercise training in patients with pulmonary arterial hypertension: A case report.Cardiopulm. Phys. Ther. J.2009204121810.1097/01823246‑200920040‑0000320467524
     [Google Scholar]
  13. TalwarA. SahniS. VermaS. KhanS.Z. DharS. KohnN. Exercise tolerance improves after pulmonary rehabilitation in pulmonary hypertension patients.J. Exerc. Rehabil.201713221421710.12965/jer.1732872.43628503536
     [Google Scholar]
/content/journals/nemj/10.2174/0102506882333573241119082734
Loading
Diagnosis and Management of Group 3 Pulmonary Hypertension in the UAE: Pulmonary Hypertension Associated with Chronic Lung Disease (PH-CLD)
NEW Emirates Medical J 5, e02506882333573 (2024); https://doi.org/10.2174/0102506882333573241119082734
/content/journals/nemj/10.2174/0102506882333573241119082734
/content/journals/nemj/10.2174/0102506882333573241119082734
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Cardiopulmonary rehabilitation programmes; Chronic lung disease; Precapillary; Pulmonary hypertension; Right heart catheterization; Vasodilators

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test